NewStem Biotechnologies is Drug Discovery in United States that focus on cell therapy business. Founded in 2018. They cover business area such as developer, somatic cell transfer, Natick, Massachusetts, advanced cell nuclear transfer, embryonic stem cell, human pluripotent cell line, autologous and allogeneic regenerative medicine, cell therapy, medical practitioner, biomedical research, diagnosis, treatment.
2018
( 6 years old in 2024 )
Cell Therapy
-
21 Strathmore Road
Natick, MA 01760
United States
Private
developersomatic cell transferNatickMassachusettsadvanced cell nuclear transferembryonic stem cellhuman pluripotent cell lineautologous and allogeneic regenerative medicinecell therapymedical practitionerbiomedical researchdiagnosistreatment
* We use standard office opening hours in near NewStem Biotechnologies's location as default value for unknown and outdated data. For more valid info, please verify the info from more trusted sources like GoogleMyBusiness, Yelp, FourSquare or similar services.
NewStem Biotechnologies is Drug Discovery business from United States that founded in 2018 (6 years old in 2024), NewStem Biotechnologies business is focusing on Cell Therapy.
NewStem Biotechnologies headquarter office and corporate office address is located in 21 Strathmore Road Natick, MA 01760 United States.
NewStem Biotechnologies was founded in United States.
In 2024, NewStem Biotechnologies is currently focus on cell therapy sector.
Above is snippet of Google Trends for "cell therapy" term, if you have problem loading the snippet, please visit here: Google Trend.
Disclaimer: This website is not affiliated with NewStem Biotechnologies, any government agency, does not create this data, vouch for its accuracy, or guarantee that it is the most recent data available. The data displayed is available through open government websites and public online directory. This website expressly disclaims the accuracy, adequacy, or completeness of any data and shall not be liable for any errors, omissions or other defects in, delays or interruptions in such data, or for any actions taken in reliance thereon.
